Establishment of individualized dosage regimen based on pharmacodynamic model considering efficacy expression process of biological agents for rheumatoid arthritis

Research Project

Project/Area Number	21590181
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	Medical pharmacy
Research Institution	Tokyo University of Pharmacy and Life Science
Principal Investigator	YAMADA Yasuhiko 東京薬科大学, 薬学部, 教授 (40158225)
Project Period (FY)	2009 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000) Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2009: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Keywords	医薬品情報・安全性学 / 投与設計 / 臨床 / 薬剤反応性 / 薬学 / 遺伝子 / リウマチ / TNFα / 薬物反応生 / モデリング
Research Abstract	Based on pharmacodynamic model for pharmacotherapy of rheumatoid arthritis, it was thought that the effect of infliximab appeared comparatively early, although its variation was large. In contrast, the effects of adalimumab and etanerscept appeared slowly, whereas these were stably. Regarding the individual variation, the level of TNFα by the influence of single nucleotide polymorphisms(SNPs) in TNFα gene was different. It was considered that dosage regimen of each drug for individual patient can be established with the developed model in view of the individual quantitative factor of TNFα.

Report

(4 results)